Category: Newsletters
UNC-CH NORC July 2020 Newsletter
UNC-CH NORC July 2020 Newsletter
Categories: Featured News, News, Newsletters Tags: University of North Carolina at Chapel HillUNC-CH NORC April 2020 Newsletter
UNC-CH NORC April 2020 Newsletter
Categories: Featured News, News, Newsletters, Uncategorized Tags: University of North Carolina at Chapel HillUNC-CH NORC January 2020 Newsletter
UNC-CH NORC January 2020 Newsletter
Categories: Featured News, News, Newsletters Tags: University of North Carolina at Chapel HillNORCH Bulletin May 2020
NORCH Newsletter May 2020 (Issue #21)
Categories: Featured News, News, Newsletters, UncategorizedNORCH Bulletin March 2020
NORCH Newsletter March 2020 (Issue #20)
Categories: Featured News, News, Newsletters, UncategorizedNORCH Bulletin January 2020
NORCH Newsletter January 2020 (Issue #19)
Categories: Featured News, News, Newsletters Tags: Harvard Medical SchoolNORCH Bulletin November 2019
NORCH Newsletter November 2019 (Issue #18)
Categories: Featured News, News, Newsletters Tags: Harvard Medical SchoolNORCH Bulletin September 2019
NORCH Bulletin September 2019 (Issue #17)
Categories: Featured News, News, Newsletters Tags: Harvard Medical SchoolNORCH Bulletin June 2019
NORCH Bulletin June 2019 (Issue #16)
Categories: Featured News, News, Newsletters Tags: Harvard Medical SchoolNORCH Bulletin April 2019
NORCH Bulletin April 2019 Research Spotlight: SGLT2 Inhibition Reprograms Systemic Metabolism via FGF21-Dependent and – Independent Mechanisms Sodium/glucose cotransporter-2 (SGLT2) inhibitors are a relatively new class of antidiabetic medications that inhibit renal glucose reabsorption, increasing glucosuria and lowering serum glucose. More recently, SGLT2 inhibitors have been shown to cause modest weight loss, improve cardiovascular risk, and reduce mortality – effects that are not adequately explained by increased glucosuria. Drs. Patti, Gerszten, and colleagues used an integrated transcriptomic-metabolomics approach to identify molecular mediators of the SGLT2 inhibitor canagliflozin in obese, non-diabetic mice. Results demonstrate that SGLT2 inhibitors modulate key nutrient-sensing pathways, activating 5’ AMP-activated protein kinase (AMPK), inhibiting mechanistic target of rapamycin (mTOR), … Read More »
Categories: Featured News, News, Newsletters Tags: Harvard Medical School